diabetes
When you need to give yourself a whole new image, there's nothing like changing your name. Which may be why high fructose corn syrup, the scourge of dieticians and dieters everywhere, wants to rebrand itself "corn sugar." But there's one big obstacle: the sugar industry, which is going to court to protect its good name.
Pharmaceuticals Look Beyond Medications to Smartphone Apps
11:10AM 2/16/2011
Health Care, Pfizer, Qualcomm, Apple, Sanofi Aventis, Merck, GlaxoSmithKline, Novartis, Cisco Systems
Pharmaceutical companies looking for fresh sources of profit are increasingly investing in a range of health care innovations that aren't drugs at all, from smartphone apps and educational websites to social media platforms and wireless devices, reports Ernst & Young.
As Diabetes Explodes, Big Pharma Is Gearing Up
6:00PM 1/27/2011
Investing, Health Care, Bristol-Myers Squibb, Sanofi Aventis, Merck, GlaxoSmithKline, Eli Lilly, Astrazeneca
Diabetes is a growing global scourge, but for Big Pharma it's more of a lifesaver -- and many drugmakers are cranking up their research efforts. After all, many existing drugs will soon be losing their patents, and diabetes could be a $55 billion market by 2019.
Abbott Laboratories Recalls 359 Million Diabetes Test Strips
7:15PM 12/22/2010
Abbott Laboratories is recalling roughly 359 million blood-sugar test strips for diabetics after the strips turned out to yield falsely low readings.
The CDC: Number of Americans With Diabetes Projected to Soar
11:00AM 10/31/2010
As many as one-third of American adults could develop diabetes in the next 40 years, according to a new analysis by the Centers for Disease Control and Prevention. The disease is also among the most expensive chronic illnesses to treat, and is considered one of the culprits in rising health care costs.
Diabetics who undergo weight-loss surgery have been found to need fewer medications and have lower health-care costs.
Around 75 percent of obese patients with Type 2 diabetes were able to stop insulin and other blood-sugar controlling drugs within six months of bariatric surgery, according to a...
'Fructose-Slurping' Cancer Could Sour the Soda Business
1:45PM 8/13/2010
Soda and processed-food makers insist that all sugars are the same. Yet with studies linking fructose to obesity, diabetes and, most recently, pancreatic cancer, big brands are quietly backing away from using corn-based high-fructose sweetener. Could it eventually become another tobacco-like liability?
MannKind Soars after FDA Accepts Resubmission of Inhaled Insulin
2:08PM 7/20/2010
MannKind shares jumped about 10% in afternoon trading after the pharmaceutical company announced the Food and Drug Administration accepted its resubmission of its inhaled insulin, Afrezza. The FDA set a review date for Dec. 29.
GlaxoSmithKline diabetes drug Avandia has been found to have increased heart attack risk compared to similar medication. But a majority of the Food and Drug Administration's panel of outside experts have voted to keep the drug on the market -- though new restrictions are likely.
On Tuesday, the FDA will convene a panel of experts to discuss GlaxoSmithKline's type II diabetes drug Avandia. Once a blockbuster, sales of the drug have dropped by more than half since studies suggested it significantly increases risk for serious heart problems.
More Stories
Next Page →Market Movers
| Symbol | Last | Change / % | Volume |
|---|
Most Actives
| 8.07 | -0.11 -1.34% | 254.23M | |
| 2.19 | +0.25 +12.89% | 122.18M | |
| 18.88 | -0.26 -1.33% | 109.55M | |
| 12.44 | -0.25 -1.97% | 52.49M |
% Gainers
| 31.68 | +7.78 +32.55% | 18.42M | |
| 89.96 | +13.57 +17.76% | 13.27M | |
| 2.19 | +0.25 +12.89% | 122.18M | |
| 10.50 | +1.10 +11.70% | 3.07M |
% Losers
DailyFinance Wire
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
- Why Used Car Bargains Are Getting Harder to Find
- 5 Reasons Facebook Stock May Be a Better Buy Than You Think
Newswire
- Greece's grim choice: deep budget cuts or...
- Greece's coalition party leaders back bailout...
- Deadline nears, Obama wants payroll tax cut...
- NY cable dispute blacks out Knicks, 4 NHL teams
- Staff at The Sun tabloid arrested in bribe...
- Turbo-traders take Bank of America for a ride
- Justice Department calls Swiss Bank a...
- As Facebook IPO nears, the case for dull stocks
- Getting paid $35,000 to short sell
- What the $26B settlement means for you
- Investing your emergency cash: Return vs. risk
- First Premier's $400-a-year credit card
- Big banks' bloated mortgage tab
- Fewer young adults hold jobs than ever before
- Government assistance expands
- Bob Rodriguez: The best advice I ever got
- 24/7 Wall St. Top Analyst Calls of the Week (AONE, ALU, AMSC, NLY, AAPL, CSCO, COH, CSTR, COP, DLR, IBM, LF, MMM, M, OPEN, POST, SIRI, SOHU, TRLG, ZOLT)
- The Force: Star Wars Franchise Worth Over $30 Billion and Growing
- 24/7 Wall St. Closing Bell (COP, GILD, AMSC, MA, COH, LNKD, ATVI, CPST, GPRE, KONA, TRLG, LGF, MOVE, NBL, PCYC, ALU, FLIR, RUTH, FSLR, CIE, TBAC, RPXC, AMRS)
- Mid-day Movers (CIE, AMRS, IPSU, MOVE, LNKD)
- Petrobras Shares Volatile on $225 Billion Development Plan (PBR)
- Morning Movers (CIE, ALU, LNKD, AMRS, XIDE)
- AEP Dividend Growth Still Looks Safe Ahead (AEP)
- Arch Coal Tumbles on Earnings, Forecast (ACI, ANR, PCX, BTU, CNX)
Follow Us
